Bodal Chemicals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹863 Cr +79.8% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
BC

Bodal Chemicals Ltd

Q4 FY25Chemicals & Petrochemicals

Bodal Chemicals Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹451Cr
+14.5% YoY
+1.8% QoQ
Net profit
₹14Cr
+600% YoY
+180% QoQ
Margin
10%
+4 pp YoY
0 pp QoQ
Price₹79
Market cap₹950 Cr
P/E13.8

The short version

FY'26 revenue is targeted at Rs. 1,900 crores plus, representing about 10% growth over FY'25. FY'26 top-line expected around Rs. 1,900 - 2,000 crores, approx. 10% growth from FY'25.

From Bodal Chemicals Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • FY'26 revenue is targeted at Rs. 1,900 crores plus, representing about 10% growth over FY'25.
  • EBITDA margins expected at 11%-12% in FY'26, improving from FY'25 Q4 levels.
  • Dye intermediate volumes to remain flat in FY'26 and FY'27, having achieved over 70% utilization.
  • Dyestuff volumes projected to grow 10%-15% in FY'26 supported by better end-user demand.
  • Benzene derivatives segment aims to increase utilization from ~30% to 60%-70% in FY'26, targeting 80% long-term.
  • Caustic soda division expects 5%-10% volume growth in FY'26 with strong margins.
  • Basic chemicals volume and revenue expected to remain stable, similar to FY'25.

2 more points from Bodal Chemicals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Bodal Chemicals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • No major CAPEX planned for FY'26; focus is on increasing utilization and reducing losses (especially in benzene derivatives).
  • Small expansion possible at Rajpura caustic chlorine unit with low CAPEX, planned anytime as a brownfield project.
  • Large-sized investments or expansions likely from FY'27 onwards or later, after improving debt-equity ratios and stabilizing businesses.
  • FY'27 could see sizable CAPEX after achieving 15-20% growth and stabilizing newer opportunities.

2 more points from Bodal Chemicals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Bodal Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion primarily focuses on: - Operational performance across different product segments. - Volume utilization and capacity utilization plans for various chemical products. - Business outlook and growth expectations (e.g., aiming for utilization increases, anticipated growth in dyestuff volumes, stability in intermediate volumes).

2 more points from Bodal Chemicals Ltd's call on order book

Create a free account to keep reading this call

Bodal Chemicals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Bodal Chemicals Ltd Q4 FY25 results — key figures

Bodal Chemicals Ltd Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue451394+14.5%443+1.8%
Operating profit (EBITDA)4725+88%44+6.8%
Operating margin10%6%+4 pp10%0 pp
Profit before tax12-2—8+50%
Net profit (PAT)142+600%5+180%
EPS (₹)1.150.16+618.7%0.43+167.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹863 Cr, net profit ₹81 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Atul (Q4 FY25)

    Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key concall takeaways from Atul Ltd's Q4…

  • Vidhi Specialty (Q4 FY25)

    109.5 Crs, up 40.2% YoY (from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Chemcon Speciality Chemicals (Q4 FY25)

    54.9 Crs, down 8% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Valiant Organics (Q4 FY25)

    Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10)…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Bodal Chemicals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Bodal Chemicals Ltd Q4 FY25 results?

FY'26 revenue is targeted at Rs. 1,900 crores plus, representing about 10% growth over FY'25. FY'26 top-line expected around Rs. 1,900 - 2,000 crores, approx. 10% growth from FY'25.

What is Bodal Chemicals Ltd share price analysis?

Bodal Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 13.8 with a market cap of ₹950 Cr. Investors should review the full earnings analysis for detailed insights.

Is Bodal Chemicals Ltd planning capital expenditure?

No major CAPEX planned for FY'26; focus is on increasing utilization and reducing losses (especially in benzene derivatives).

Keep Bodal Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.